Regeneron Pharmaceuticals' Capital Expenditures rose 2459.92% to $248.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $898.4 million, marking a year-over-year increase of 1885.17%. This contributed to the annual value of $898.4 million for FY2025, which is 1885.17% up from last year.
Regeneron Pharmaceuticals' Capital Expenditures amounted to $248.7 million in Q4 2025, which was up 2459.92% from $201.4 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Capital Expenditures registered a high of $251.4 million during Q4 2023, and its lowest value of $113.0 million during Q2 2023.
Moreover, its 5-year median value for Capital Expenditures was $165.4 million (2021), whereas its average is $175.7 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Capital Expenditures plummeted by 3221.63% in 2021, and later surged by 7124.72% in 2025.
Regeneron Pharmaceuticals' Capital Expenditures (Quarter) stood at $154.9 million in 2021, then fell by 1.74% to $152.2 million in 2022, then surged by 65.18% to $251.4 million in 2023, then dropped by 20.6% to $199.6 million in 2024, then rose by 24.6% to $248.7 million in 2025.
Its Capital Expenditures stands at $248.7 million for Q4 2025, versus $201.4 million for Q3 2025 and $219.0 million for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value